Skip to content

Public FDA record

Z-2143-2020: Bridge Occlusion Balloon, REF 590-001, QTY 1, Sheath Compatibility 12F, Guidewire Compatibility 0.035 in,

Recall record Z-2143-2020 for Spectranetics Corporation. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-2143-2020
Company in FDA record
Spectranetics Corporation
FDA record creation date
Jun 1, 2020
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

There is a potential for thrombus formation on balloons prepped and staged in the vasculature for long durations. All users, such as those performing lead extraction cases may not be aware of this risk. It was determined that current labeling is insufficient to ensure all potential users minimize the time the balloon remains in vasculature. If left in too long it could lead to embolization.

Source facts

Action
A Field Safety Notification dated 3/31/20 was to be sent to all consignees utilizing regional sales managers and territory managers responsible for each customer account, beginning on March 31, 2020 via email or delivery in person depending on each account's restrictions due to COVID-19. The purpose of the letter was to to provide customers with an update regarding the Bridge occlusion balloon. They recently were made aware of an unpublished physician study that suggests potential formation of thrombus on the Bridge occlusion balloon when staged in patients for an extended period of time. It describes the risks to health as follows: The preliminary study results suggest that intravascular balloon staging with prolonged dwell times (average of 176 118 minutes) may be associated with an increased risk of thrombus formation. This study had one reported pulmonary embolism identified 3 days post procedure, which has not been attributed to the device. The rate of occurrence of the risk of harm is deemed to be remote (0.0108%), as no additional complaints for thrombus formation have been reported over the lifetime of the device outside of this preliminary study. This rate is within the expected range for lead extraction per HRS guidelines. The safety of the Bridge occlusion balloon has been well-proven among thousands of lead extractions over the last several years and remains effective in occluding SVC tears, significantly reducing the probability of mortality when used properly. Due to the rapid rate of blood loss associated with SVC tears, the Bridge device may be staged prophylactically to limit the time to occlusion. Actions to be taken by the Healthcare Professional: Inform potential users of the product in your organization of this notification, and complete and return the attached customer response form. At this time, the recommendation from their Medical Advisory Board is; when utilizing Bridge prophylactically, consider deployment after lead prepara
Initiated
2020-03-31
Root cause
Labeling design
Terminated
2022-10-31
Distribution
US: Nationwide OUS: Australia, Austria, Belgium, Canada, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Japan, Jordan, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, The Netherlands, and the United Kingdom of Great Britain and Northern Ireland
Recall number
Z-2143-2020
Recall status
Terminated
CDRH record ID
181053
FDA record created
2020-06-01
Recall event number
85477

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗